Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

AUPH Stock Forecast

Aurinia Pharmaceuticals stock forecast is as follows: an average price target of $10.75 (represents a 22.58% upside from AUPH’s last price of $8.77) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

AUPH Price Target

The average price target for Aurinia Pharmaceuticals (AUPH) is $10.75 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $6.00. This represents a potential 22.58% upside from AUPH's last price of $8.77.

AUPH Analyst Ratings

Buy

According to 4 Wall Street analysts, Aurinia Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AUPH stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Aurinia Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 06, 2024	Ed Arce	H.C. Wainwright	$13.00	$6.91	88.13%	48.23%
May 02, 2024	Maury Raycroft	Jefferies	$6.00	$5.10	17.65%	-31.58%
Jan 04, 2023	-	RBC Capital	$11.00	$5.94	85.19%	25.43%
Aug 09, 2022	-	H.C. Wainwright	$26.00	$8.27	214.39%	196.47%
Aug 08, 2022	-	Oppenheimer	$13.00	$8.37	55.32%	48.23%
May 05, 2022	-	H.C. Wainwright	$30.00	$11.37	163.85%	242.08%
Apr 28, 2022	-	RBC Capital	$22.00	$10.41	111.34%	150.86%

Row per page

Go to

The latest Aurinia Pharmaceuticals stock forecast, released on Sep 06, 2024 by Ed Arce from H.C. Wainwright, set a price target of $13.00, which represents a 88.13% increase from the stock price at the time of the forecast ($6.91), and a 48.23% increase from AUPH last price ($8.77).

Aurinia Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	2
Avg Price Target	-	$13.00	$9.50
Last Closing Price	$8.77	$8.77	$8.77
Upside/Downside	-100.00%	48.23%	8.32%

In the current month, the average price target of Aurinia Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aurinia Pharmaceuticals's last price of $8.77. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 06, 2024	H.C. Wainwright	Buy	Buy	Hold
May 02, 2024	Jefferies	Hold	Hold	Hold
Jan 04, 2023	RBC Capital	Outperform	Outperform	Hold
Aug 08, 2022	Oppenheimer	Outperform	Outperform	Hold
Apr 28, 2022	RBC Capital	Outperform	Outperform	Hold
Feb 23, 2022	RBC Capital	Outperform	Outperform	Hold
Dec 10, 2021	Oppenheimer	-	Outperform	Upgrade

Row per page

Go to

Aurinia Pharmaceuticals's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave AUPH a "Buy" rating, the same as its previous rate.

Aurinia Pharmaceuticals Financial Forecast

Aurinia Pharmaceuticals Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	$42.31M	$40.78M	$41.49M	$34.41M	$28.43M	$55.78M	$28.19M	$21.63M	$23.40M	$14.67M	$6.62M	$914.00K	$50.03M	$29.00K	$29.00K	$30.00K	$29.00K	$230.00K	$29.00K	$30.00K	$30.00K	$31.00K
Avg Forecast	$74.63M	$70.80M	$69.00M	$64.37M	$61.55M	$57.48M	$54.25M	$47.07M	$45.00M	$38.44M	$37.90M	$27.87M	$27.77M	$36.19M	$27.04M	$19.23M	$22.00M	$13.87M	$4.96M	$3.03M	$12.53M	$43.43K	$27.56K	$37.00K	$61.71K	$41.50K	$44.00K	$38.00K	$28.33K	$3.91K
High Forecast	$79.15M	$75.08M	$73.17M	$66.52M	$69.99M	$58.17M	$54.25M	$47.07M	$46.59M	$39.94M	$40.19M	$29.56M	$29.45M	$36.19M	$27.04M	$19.23M	$22.00M	$13.87M	$4.96M	$3.03M	$12.53M	$43.43K	$27.56K	$37.00K	$61.71K	$41.50K	$44.00K	$38.00K	$34.00K	$4.69K
Low Forecast	$71.06M	$67.41M	$65.70M	$62.21M	$56.80M	$56.79M	$54.25M	$47.07M	$42.54M	$36.44M	$36.08M	$26.54M	$26.44M	$36.19M	$27.04M	$19.23M	$22.00M	$13.87M	$4.96M	$3.03M	$12.53M	$43.43K	$27.56K	$37.00K	$61.71K	$41.50K	$44.00K	$38.00K	$22.66K	$3.13K
# Analysts	1	1	1	2	5	4	1	1	3	8	5	4	4	3	4	3	5	4	5	4	5	5	9	6	4	4	7	4	11	18
Surprise %	-	-	-	-	-	-	-	-	0.94%	1.06%	1.09%	1.23%	1.02%	1.54%	1.04%	1.12%	1.06%	1.06%	1.33%	0.30%	3.99%	0.67%	1.05%	0.81%	0.47%	5.54%	0.66%	0.79%	1.06%	7.92%

Aurinia Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $47.07M, with a low forecast of $47.07M, and a high forecast of $47.07M. AUPH's average Quarter revenue forecast represents a 11.25% increase compared to the company's last Quarter revenue of $42.31M (Dec 23).

Aurinia Pharmaceuticals EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	5	4	1	1	3	8	5	4	4	3	4	3	5	4	5	4	5	5	9	6	4	4	7	4	11	18
EBITDA	-	-	-	-	-	-	-	-	$-29.67M	$-16.26M	$-11.35M	$-29.58M	$-28.10M	$-8.69M	$-35.15M	$-37.04M	$-31.80M	$-49.46M	$-46.15M	$-49.51M	$-22.09M	$-33.50M	$-28.93M	$-16.34M	$-75.99M	$-18.61M	$-15.38M	$-12.02M	$-14.84M	$-51.50M
Avg Forecast	$-61.68M	$-58.52M	$-57.03M	$-53.20M	$-50.87M	$-47.51M	$-44.84M	$-44.19M	$-37.19M	$-31.77M	$-31.32M	$-40.17M	$-32.04M	$-30.69M	$-22.93M	$-36.52M	$-18.65M	$-11.76M	$-4.21M	$-44.16M	$-10.63M	$-36.83K	$-23.37K	$-21.24M	$-52.33K	$-35.19K	$-37.31K	$-12.82M	$-14.19M	$-263.05M
High Forecast	$-58.73M	$-55.72M	$-54.30M	$-51.42M	$-46.95M	$-46.94M	$-44.84M	$-35.35M	$-35.16M	$-30.12M	$-29.82M	$-32.14M	$-25.64M	$-30.69M	$-22.93M	$-29.22M	$-18.65M	$-11.76M	$-4.21M	$-35.33M	$-10.63M	$-36.83K	$-23.37K	$-17.00M	$-52.33K	$-35.19K	$-37.31K	$-10.26M	$-11.35M	$-210.44M
Low Forecast	$-65.42M	$-62.06M	$-60.48M	$-54.98M	$-57.85M	$-48.08M	$-44.84M	$-53.03M	$-38.51M	$-33.01M	$-33.22M	$-48.21M	$-38.45M	$-30.69M	$-22.93M	$-43.82M	$-18.65M	$-11.76M	$-4.21M	$-53.00M	$-10.63M	$-36.83K	$-23.37K	$-25.49M	$-52.33K	$-35.19K	$-37.31K	$-15.39M	$-17.03M	$-315.66M
Surprise %	-	-	-	-	-	-	-	-	0.80%	0.51%	0.36%	0.74%	0.88%	0.28%	1.53%	1.01%	1.70%	4.21%	10.97%	1.12%	2.08%	909.55%	1238.20%	0.77%	1452.05%	528.94%	412.13%	0.94%	1.05%	0.20%

undefined analysts predict AUPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aurinia Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Aurinia Pharmaceuticals Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	5	4	1	1	3	8	5	4	4	3	4	3	5	4	5	4	5	5	9	6	4	4	7	4	11	18
Net Income	-	-	-	-	-	-	-	-	$-26.88M	$-13.45M	$-11.49M	$-26.21M	$-26.05M	$-8.99M	$-35.52M	$-37.63M	$-33.32M	$-50.26M	$-47.01M	$-50.38M	$-22.56M	$-34.06M	$-29.53M	$-16.53M	$-76.48M	$-19.04M	$-15.90M	$-12.43M	$-15.48M	$-51.94M
Avg Forecast	$25.25M	$20.88M	$19.42M	$16.02M	$971.05K	$2.18M	$1.21M	$-45.53M	$-23.79M	$-24.34M	$-26.70M	$-41.39M	$-33.46M	$-33.43M	$-31.91M	$-37.63M	$-38.70M	$-47.97M	$-52.60M	$-44.78M	$-28.46M	$-33.56M	$-33.31M	$-21.49M	$-29.03M	$-27.14M	$-22.77M	$-13.26M	$-14.57M	$-264.90M
High Forecast	$27.23M	$22.52M	$20.95M	$17.28M	$2.22M	$2.36M	$1.24M	$-36.43M	$-18.50M	$-18.62M	$-25.04M	$-33.11M	$-26.77M	$-33.43M	$-31.91M	$-30.10M	$-38.70M	$-47.97M	$-52.60M	$-35.83M	$-28.46M	$-33.56M	$-33.31M	$-17.20M	$-29.03M	$-27.14M	$-22.77M	$-10.61M	$-11.65M	$-211.92M
Low Forecast	$23.68M	$19.58M	$18.21M	$14.57M	$-832.33K	$2.05M	$1.19M	$-54.64M	$-31.72M	$-27.21M	$-28.80M	$-49.67M	$-40.16M	$-33.43M	$-31.91M	$-45.16M	$-38.70M	$-47.97M	$-52.60M	$-53.74M	$-28.46M	$-33.56M	$-33.31M	$-25.79M	$-29.03M	$-27.14M	$-22.77M	$-15.91M	$-17.48M	$-317.88M
Surprise %	-	-	-	-	-	-	-	-	1.13%	0.55%	0.43%	0.63%	0.78%	0.27%	1.11%	1.00%	0.86%	1.05%	0.89%	1.13%	0.79%	1.02%	0.89%	0.77%	2.63%	0.70%	0.70%	0.94%	1.06%	0.20%

Aurinia Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AUPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Aurinia Pharmaceuticals SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	5	4	1	1	3	8	5	4	4	3	4	3	5	4	5	4	5	5	9	6	4	4	7	4	11	18
SG&A	-	-	-	-	-	-	-	-	$50.07M	$47.76M	$47.08M	$50.12M	$47.47M	$52.17M	$51.53M	$45.20M	$44.24M	$44.13M	$43.79M	$39.28M	$38.31M	$31.07M	$15.54M	$11.06M	$7.25M	$6.06M	$4.95M	$3.90M	$3.79M	$3.43M
Avg Forecast	$1.16B	$1.10B	$1.08B	$1.00B	$959.20M	$895.75M	$845.44M	$733.58M	$701.26M	$599.00M	$590.57M	$434.38M	$432.81M	$563.90M	$421.42M	$299.68M	$342.76M	$216.13M	$77.30M	$47.19M	$195.34M	$676.77K	$429.42K	$576.59K	$961.72K	$646.71K	$685.67K	$592.17K	$441.53K	$60.98K
High Forecast	$1.23B	$1.17B	$1.14B	$1.04B	$1.09B	$906.54M	$845.45M	$733.59M	$726.05M	$622.34M	$626.29M	$460.66M	$458.98M	$563.90M	$421.42M	$299.68M	$342.76M	$216.13M	$77.30M	$47.19M	$195.34M	$676.77K	$429.42K	$576.59K	$961.72K	$646.71K	$685.67K	$592.17K	$529.81K	$73.15K
Low Forecast	$1.11B	$1.05B	$1.02B	$969.52M	$885.17M	$884.95M	$845.44M	$733.58M	$662.94M	$567.89M	$562.32M	$413.61M	$412.10M	$563.90M	$421.42M	$299.68M	$342.76M	$216.13M	$77.30M	$47.19M	$195.34M	$676.77K	$429.42K	$576.59K	$961.72K	$646.71K	$685.67K	$592.17K	$353.20K	$48.76K
Surprise %	-	-	-	-	-	-	-	-	0.07%	0.08%	0.08%	0.12%	0.11%	0.09%	0.12%	0.15%	0.13%	0.20%	0.57%	0.83%	0.20%	45.91%	36.19%	19.18%	7.53%	9.37%	7.21%	6.59%	8.59%	56.20%

Aurinia Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $733.58M, based on 1 Wall Street analysts, with a range of $733.58M to $733.59M. The forecast indicates a 1365.06% rise compared to AUPH last annual SG&A of $50.07M (Dec 23).

Aurinia Pharmaceuticals EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	5	4	1	1	3	8	5	4	4	3	4	3	5	4	5	4	5	5	9	6	4	4	7	4	11	18
EPS	-	-	-	-	-	-	-	-	$-0.19	$-0.09	$-0.08	$-0.18	$-0.18	$-0.06	$-0.25	$-0.27	$-0.25	$-0.39	$-0.37	$-0.40	$-0.05	$-0.28	$-0.26	$-0.15	$-0.78	$-0.21	$-0.17	$-0.14	$-0.18	$-0.92
Avg Forecast	$0.17	$0.14	$0.13	$0.11	$0.01	$0.01	$0.01	$-0.14	$-0.16	$-0.17	$-0.18	$-0.22	$-0.27	$-0.23	$-0.22	$-0.27	$-0.27	$-0.33	$-0.36	$-0.37	$-0.20	$-0.23	$-0.23	$-0.19	$-0.20	$-0.19	$-0.16	$-0.15	$-0.16	$-0.61
High Forecast	$0.19	$0.15	$0.14	$0.12	$0.02	$0.02	$0.01	$-0.13	$-0.13	$-0.13	$-0.17	$-0.21	$-0.25	$-0.23	$-0.22	$-0.27	$-0.27	$-0.33	$-0.36	$-0.37	$-0.20	$-0.23	$-0.23	$-0.19	$-0.20	$-0.19	$-0.16	$-0.15	$-0.13	$-0.49
Low Forecast	$0.16	$0.13	$0.13	$0.10	$-0.01	$0.01	$0.01	$-0.15	$-0.22	$-0.19	$-0.20	$-0.24	$-0.29	$-0.23	$-0.22	$-0.27	$-0.27	$-0.33	$-0.36	$-0.37	$-0.20	$-0.23	$-0.23	$-0.19	$-0.20	$-0.19	$-0.16	$-0.15	$-0.19	$-0.73
Surprise %	-	-	-	-	-	-	-	-	1.16%	0.56%	0.44%	0.81%	0.67%	0.27%	1.13%	1.01%	0.93%	1.17%	1.01%	1.08%	0.25%	1.20%	1.13%	0.78%	3.87%	1.12%	1.08%	0.96%	1.13%	1.51%

According to undefined Wall Street analysts, Aurinia Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AUPH previous annual EPS of $NaN (undefined).

Aurinia Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
BTAI	BioXcel Therapeutics	$0.57	$12.00	2005.26%	Buy
TERN	Terns Pharmaceuticals	$5.71	$14.25	149.56%	Buy
VKTX	Viking Therapeutics	$51.63	$102.40	98.33%	Buy
MCRB	Seres Therapeutics	$0.73	$1.25	71.23%	Buy
SRPT	Sarepta Therapeutics	$110.50	$169.06	53.00%	Buy
AKRO	Akero Therapeutics	$31.20	$46.00	47.44%	Buy
AXSM	Axsome Therapeutics	$98.19	$122.42	24.68%	Buy
AUPH	Aurinia Pharmaceuticals	$8.77	$10.75	22.58%	Buy
PTCT	PTC Therapeutics	$42.89	$46.50	8.42%	Hold
MDGL	Madrigal Pharmaceuticals	$329.24	$315.75	-4.10%	Buy
EXEL	Exelixis	$34.83	$30.50	-12.43%	Buy
TGTX	TG Therapeutics	$34.55	$27.60	-20.12%	Buy

AUPH Forecast FAQ

Is Aurinia Pharmaceuticals a good buy?

Yes, according to 4 Wall Street analysts, Aurinia Pharmaceuticals (AUPH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of AUPH's total ratings.

What is AUPH's price target?

Aurinia Pharmaceuticals (AUPH) average price target is $10.75 with a range of $6 to $13, implying a 22.58% from its last price of $8.77. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Aurinia Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for AUPH stock, the company can go up by 22.58% (from the last price of $8.77 to the average price target of $10.75), up by 48.23% based on the highest stock price target, and down by -31.58% based on the lowest stock price target.

Can Aurinia Pharmaceuticals stock reach $13?

AUPH's average twelve months analyst stock price target of $10.75 does not support the claim that Aurinia Pharmaceuticals can reach $13 in the near future.

What are Aurinia Pharmaceuticals's analysts' financial forecasts?

Aurinia Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $220.36M (high $229.49M, low $214.92M), average EBITDA is $-187M (high $-174M, low $-204M), average net income is $-41.163M (high $-30.612M, low $-52.233M), average SG&A $3.43B (high $3.58B, low $3.35B), and average EPS is $-0.107 (high $-0.0883, low $-0.131). AUPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $278.8M (high $293.92M, low $266.39M), average EBITDA is $-230M (high $-220M, low $-243M), average net income is $81.56M (high $87.98M, low $76.03M), average SG&A $4.34B (high $4.58B, low $4.15B), and average EPS is $0.56 (high $0.604, low $0.522).

Did the AUPH's actual financial results beat the analysts' financial forecasts?

Based on Aurinia Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $158.53M, beating the average analysts forecast of $149.21M by 6.25%. Apple's EBITDA was $-91.691M, missing the average prediction of $-140M by -34.72%. The company's net income was $-78.02M, missing the average estimation of $-116M by -32.87%. Apple's SG&A was $195.04M, missing the average forecast of $2.33B by -91.61%. Lastly, the company's EPS was $-0.54, missing the average prediction of $-0.735 by -26.55%. In terms of the last quarterly report (Dec 2023), Aurinia Pharmaceuticals's revenue was $42.32M, missing the average analysts' forecast of $45M by -5.97%. The company's EBITDA was $-29.674M, missing the average prediction of $-37.193M by -20.22%. Aurinia Pharmaceuticals's net income was $-26.875M, beating the average estimation of $-23.789M by 12.97%. The company's SG&A was $50.07M, missing the average forecast of $701.26M by -92.86%. Lastly, the company's EPS was $-0.19, beating the average prediction of $-0.163 by 16.33%